The ASF1B, CD82B, and CRISP3 expression levels were found to be statistically significantly downregulated, while the expression levels of FN1, MEF2B, PD-L1, PPARγ, and TERT were increased in MM patients compared to the NCBD group; the complex biomarker (the CRISP3/TIMP1 expression ratio) was shown to be a potential prognostic biomarker in MM. This evidence concerns the gene FN1 and Miyoshi myopathy.